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A novel recombinant multiepitope protein (MEP) has been designed that consists of four linear, immuno-
dominant, and phylogenetically conserved epitopes, taken from human immunodeficiency virus (HIV)-encoded
antigens that are used in many third-generation immunoassay kits. This HIV-MEP has been evaluated for its
diagnostic potential in the detection of anti-HIV antibodies in human sera. A synthetic MEP gene encoding
these epitopes, joined by flexible peptide linkers in a single open reading frame, was designed and overex-
pressed in Escherichia coli. The recombinant HIV-MEP was purified using a single affinity step, yielding >20
mg pure protein/liter culture, and used as the coating antigen in an in-house immunoassay. Bound anti-HIV
antibodies were detected by highly sensitive time-resolved fluorometry, using europium(III) chelate-labeled
anti-human antibody. The sensitivity and specificity of the HIV-MEP were evaluated using Boston Biomedica
worldwide HIV performance, HIV seroconversion, and viral coinfection panels and were found to be compa-
rable with those of commercially available anti-HIV enzyme immunoassay (EIA) kits. The careful choice of
epitopes, high epitope density, and an E. coli-based expression system, coupled with a simple purification
protocol and the use of europium(III) chelate-labeled tracer, provide the capability for the development of an
inexpensive diagnostic test with high degrees of sensitivity and specificity.
Human immunodeficiency virus (HIV) is a lentivirus of the
family Retroviridae, whose members characteristically have an
RNA genome within a capsid and a lipid envelope. HIV in-
fection induces a profound immune dysfunction, with abnor-
malities in every arm of the immune system, resulting in AIDS
(5). In 2007, there were 2.7 million new HIV infections and 2
million HIV-related deaths. Globally, there were an estimated
33 million people living with HIV in 2007. India is one of the
largest and most populated countries in the world, with a
population of over 1 billion. Of this number, it is estimated that
around 2.4 million Indians were living with HIV in 2007 (26).
The genes of HIV are located in the central region of the
proviral DNA and encode at least nine proteins. These pro-
teins are divided into three classes: the major structural pro-
teins (Gag, Pol, and Env), the regulatory proteins (Tat and
Rev), and the accessory proteins (Vpu, Vpr, Vif, and Nef) (11).
The gag gene of HIV type 1 (HIV-1) encodes a polyprotein
precursor, p55, which is cleaved by the virus-encoded protease
into three proteins, p24, p17, and p15. Linear B-cell epitopes
have already been identified within p24 (14). The antigen p24
is of special significance because of its ability to be expressed
first in body fluids after HIV-1 infection. The linear immuno-
dominant epitope of p24 serves as an important diagnostic
intermediate to detect antibodies to HIV-1 in human sera (23).
The envelope glycoproteins (gp), gp41 of HIV-1 and gp36 of
the closely related HIV-2, are highly immunogenic and are
important diagnostic intermediates for the detection of anti-
bodies to these viruses in human sera (17, 24). HIV-1 com-
prises three lineages, denoted M, N, and O (22). HIV-2 and
divergent forms have been detected in West African or West
Africa-related patients with AIDS (7–9). Several enzyme im-
munoassay (EIA)-based diagnostic kits are available on the
market for the detection of antibodies to HIV in human sera.
These anti-HIV EIA kits use synthetic peptides and/or recom-
binant proteins mainly from the envelope gp of HIV-1 group
M, HIV-1 group O, and HIV-2. The fourth-generation kits also
have antibodies to p24 antigen. The requirement of multiple
peptides and/or multiple recombinant proteins for reliable di-
agnosis of HIV infections adds to the cost of these EIA kits.
The high cost of anti-HIV EIA kits becomes prohibitive for
routine use in many developing countries, precluding early
detection and prevention of new infections (18, 25, 27). We
have designed a single recombinant multiepitope protein
(MEP) antigen, consisting of several immunodominant, linear,
and conserved virus-specific epitopes from structural proteins
of HIV-1 and HIV-2. DNAs encoding these epitopes have
been assembled in tandem in a single open reading frame, with
intervening sequences encoding flexible linkers, and expressed
in Escherichia coli. A polyhistidine tag has also been included
which allows for facile purification of recombinant MEP by
Ni-NTA chromatography. The purified protein has been used
as the coating antigen for developing an anti-HIV indirect
immunoassay. We have evaluated the performance of this as-
say with that of other multiple-antigen-based immunoassay kits
currently available on the market, using well-characterized
commercially available serum panels.
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MATERIALS AND METHODS
Materials. E. coli host strains DH5 and BL21(DE3) were purchased from
Invitrogen Life Technologies, Carlsbad, CA. Plasmid vector pET-32a() was
obtained from Novagen, Madison, WI. The synthetic gene, codon optimized for
E. coli expression, encoding the recombinant HIV-MEP (r-HIV-MEP) was cus-
tom synthesized by Geneart, Regensburg, Germany. Restriction endonucleases,
calf intestine alkaline phosphatase, and T4 DNA ligase used in all routine
cloning and transformation experiments were procured from MBI Fermentas,
Burlington, Canada. Taq polymerase for PCR screening was an in-house prep-
aration. Ni-NTA super flow resin was purchased from Qiagen, Maryland. Goat
anti-human IgG was purchased from Pierce, Rockford, IL. Isopropyl-ß-D-thio-
galactopyranoside (IPTG) was procured from Calbiochem-EMD Biosciences, La
Jolla, CA. Well-characterized international serum panels were purchased from
Boston Biomedica Inc. (BBI), now SeraCare Life Sciences Inc., Milford, MA.
The BBI panels were the worldwide HIV performance panel (WWRB 302-01 to
WWRB 302-30), HIV seroconversion panel (PRB 931-01 to PRB 931-09), and
viral coinfection panel (PCA 201-01 to PCA 201-25). The europium(III) chelate,
{2,2,2,2-{[2-(4-isothiocyanatophenyl) ethylimino] bis (methylene)bis {4-{[4-
(-galactopyranoxy)phenyl] ethynyl}pyridine-6,2-diyl}bis (methylene-nitrilo)}
tetrakis(acetato)} europium(III), was synthesized in the Department of Biotech-
nology, Turku University, Turku, Finland. This is referred to in this paper as
Eu3-9d-chelate. The computer modeling of r-HIV-MEP was done using online
software available at http://www.sbg.bio.ic.ac.uk/3dpssm.
Cloning of synthetic r-HIV-MEP gene. A synthetic gene (0.54 kb) encoding the
r-HIV-MEP antigen, codon optimized for expression in E. coli (21), was custom
synthesized as a BamHI/HindIII fragment in the Geneart vector pPCRscript. Re-
gions of very high (80%) or very low (30%) GC content, internal TATA boxes,
chi-site stretches, internal ribosomal entry sites, AT-rich or GC-rich sequence
stretches, repeat sequences, and RNA secondary structures were avoided where
possible. The lengths of individual epitopes varied from 28 to 51 amino acid (aa)
residues, and the adjacent epitopes were joined together by flexible tetraglycyl
(Gly-Gly-Gly-Gly) linkers (20). The r-HIV-MEP gene was inserted into the expres-
sion vector pET-32a(), in frame with the vector-encoded thioredoxin gene and
six-His tag-encoding sequence, under the control of the tightly regulated T7 pro-
moter. This expression vector was transformed into E. coli strain BL21(DE3).
Expression and purification of r-HIV-MEP. Transformants harboring the r-
HIV-MEP plasmid were expression screened to choose a clone that expressed
r-HIV-MEP maximally. As the r-HIV-MEP antigen is expressed as a thioredoxin
fusion, the predicted size of the induced protein is 41 kDa (data not shown). A
localization experiment performed with this clone showed that the r-HIV-MEP
antigen was localized predominantly with the insoluble fraction of the lysate. For
purification of the recombinant antigen, a 1-liter culture was induced at log phase
with IPTG for 4 h. Bacteria from the induced culture were centrifuged in a Sorvall
SLA3000 rotor at 8,000 rpm for 10 min at 4°C, suspended in lysis buffer (6 M
guanidine HCl, 10 mM Tris-HCl, 100 mM sodium phosphate, 300 mM NaCl, 1%
Tween 20, pH 8) and sonicated, at 4°C, in a Sonics Vibracell sonicator (amplitude
setting of 60), using 20 pulses of 10 s each, with 30 s off time between the pulses. The
lysate was clarified by centrifugation at 16,000 rpm at 4°C in an SS34 rotor for 45
min. The recombinant protein from this material was purified by affinity chroma-
tography on a 5-ml Ni-NTA superflow resin column essentially as described earlier
(6).
Eu3-9d-chelate and its conjugation to anti-human antibody. The synthesis
and full description of fluorescent properties of the Eu3-9d-chelate have
been published previously (15, 19). Goat anti-human IgG was labeled using a
40-fold molar excess of the Eu3-9d-chelate. The labeling and removal of
excess free label were performed essentially as described before (19). The
protein concentration of the labeled antibody preparation was determined by
Bradford assay (3). The level of label incorporation was determined to be 2.6
Eu3-9d-chelate per antibody. Bovine serum albumin (BSA) and sodium
azide were added to final concentrations of 0.1% and 0.05%, respectively.
The solution was filtered through a 0.22-m membrane and stored at 4°C
until used further.
In-house indirect HIV immunoassay. Time-resolved fluorometry (TRF) mea-
surements of Eu3-9d-chelate-labeled anti-human antibody in indirect immuno-
assays with r-HIV-MEP as the capture antigen were made using a Victor3V 1420
Multilabel counter (Perkin Elmer, Singapore), which allows the measurement
directly from a solid phase. Briefly, 5 g/ml of r-HIV-MEP was prepared in
coating buffer (0.1 M carbonate-bicarbonate buffer, pH 9.6) and 100 l of this
was added into each well of a 96-well plate and incubated overnight at 37°C. The
wells were aspirated and blocked with 300 l of blocking buffer (37.5 mM
Tris-HCl, pH 7.75, 25% goat serum, 115 mM NaCl, 0.05% NaN3, 0.038% Tween
40, 15 M EDTA, 1.38% BSA) and incubated for 2 h at room temperature with
shaking. The wells were washed two times using COLUMBUS Plus-BASIC
(TECAN, Gro¨dig, Austria) with wash buffer (10 mM KH2PO4, 40 mM
K2HPO4, pH 7.2, 150 mM NaCl, 0.1% Tween 20, 0.5 M KCl). After washing,
2 l of each serum sample in 50 l assay buffer (37.5 mM Tris-HCl, pH 7.75,
25% goat serum, 115 mM NaCl, 0.5 M KCl, 0.05% NaN3, 0.038% Tween 40,
0.1% Triton X-100, 15 M EDTA, 0.38% BSA) was incubated in each well
for 30 min at room temperature with shaking. The wells were washed four
times with wash buffer. One microgram per milliliter of Eu3-9d-chelate
labeled anti-human antibody was made in assay buffer, and 50 l of this was
added into each well and incubated for 30 min at room temperature with
shaking. The wells were washed seven times with wash buffer, and TRF for
Eu3-9d-chelate was measured from dry wells using the following parame-
ters: excitation wavelength, 340 nm; emission wavelength, 615 nm; delay time,
400 s; window time, 400 s; cycling time, 1 ms; measurement time, 1s (i.e.,
counts resulting from 1,000 sequential excitations were integrated for each
measurement). To designate sera as either positive or negative, we used a
cutoff value of 6,500 counts/s (obtained by adding three times the standard
deviation to the mean of HIV-negative sera). Sera with a “signal-to-cutoff”
(S/Co) ratio of 1.0 were designated negative, while those with S/Co  1.0
were designated positive. To ensure the validity of the cutoff value, we
included positive- and negative-control samples in each run. All measure-
ments were made with a single lot of reagents using the same instrument.
RESULTS
Design of r-HIV-MEP antigen. To design a MEP that could
be of diagnostic utility, linear and conserved immunodominant
epitopes, known to elicit anti-HIV antibodies, were selected
based on published literature, summarized in Table 1 (10, 12, 14).
These epitopes were from HIV-1 p24 and the Env antigens of
HIV-1 and HIV-2. The r-HIV-MEP was designed by linking
these epitopes in tandem using (Gly)4 peptides. The DNA and
predicted amino acid sequence and computer modeling analysis
of the three-dimensional structure of the r-HIV-MEP are shown
in Fig. 1. Computer modeling analysis suggests that the design of
the MEP permits easy accessibility of all its constituent epitopes.
All these epitopes would therefore be freely available for inter-
action with their cognate antibodies and would contribute to the
overall sensitivity and specificity of the MEP in terms of reactivity
with patient sera. Multiple sequence alignment of the epitopes of
the r-HIV-MEP antigen with the corresponding epitopes of dif-
ferent HIV types and groups is shown in Fig. 2. It is apparent that
the epitopes selected for inclusion in r-HIV-MEP manifest a
considerable level of conservation among the specific types and
groups of HIV, suggesting that this synthetic antigen may exhibit
immunoreactivity to antibodies specific to different types and
groups of HIV.
Expression and purification of r-HIV-MEP. We expressed a
synthetic gene encoding the r-HIV-MEP protein in E. coli using
TABLE 1. List of HIV-specific immunodominant epitopes selected
from the literature in designing the r-HIV-MEP antigen
Viral protein Position of epitopes inHIV proteinsa
% positivity with
patient sera Reference
HIV-1 p24 aa 272–322 of p55 (505) NDb 14
HIV-1 group
O gp41
aa 580–616 of gp160 (863) 84 10
HIV-2 gp36 aa 587–614 of gp160 (858) 100c 12
HIV-1 group
M gp41
aa 580–625 of gp160 (853) 100 10
a Numbers in parentheses indicate the total numbers of amino acid residues of
the corresponding full-length proteins.
b ND, not done.
c In combination with HIV-1 gp41 (31 aa) and p24 (146 aa).
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IPTG induction from a 1-liter shake-flask culture. As localization
experiments showed that the r-HIV-MEP was associated exclusively
with the insoluble pellet fraction of lysates, we solubilized it using
guanidinium and purified it under denaturing conditions by Ni-NTA
affinity chromatography (data not shown). We obtained 21 mg of
95% purified protein from a liter of induced culture.
Evaluation of the r-HIV-MEP with Boston Biomedica serum
panels. Next, we sought to establish an in-house anti-HIV
FIG. 1. The r-HIV-MEP antigen designed for this study. (A) Computer-generated graphic visualization (http://www.sbg.bio.ic.ac.uk/3dpssm)
of r-HIV-MEP. (B) Complete nucleotide (lowercase letters) and predicted amino acid (capital letters) sequences of the r-HIV-MEP gene showing
four epitopes (aa 1 to 51, p24 of HIV-1; aa 56 to 92, gp41 of HIV-1 group O; aa 97 to 124, gp36 of HIV-2; and aa 129 to 174, gp41 of HIV-1 group
M) linked together with flexible tetraglycyl linkers (underlined). The asterisk indicates the engineered stop codon.
FIG. 2. Multiple sequence alignment of the four r-HIV-MEP epitopes with the corresponding epitopes of different HIV types, groups, and subtypes
(http://bioinfo.genotoul.fr/multalin/multalin.html). The black dots indicate identical residues. Variants are indicated by the standard single-letter amino acid code.
Letters in the virus names indicate subtypes. In the case of HIV-1 group O gp41, the alignment has been done with different isolates within the group.
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indirect immunoassay using the purified r-HIV-MEP. In this
assay, the purified r-HIV-MEP antigen was used to capture
anti-HIV antibodies in sera. Bound anti-HIV antibodies were
detected by TRF using anti-human antibody labeled with
Eu3-9d-chelate. To establish the specificity of r-HIV-MEP
protein as an intermediate for anti-HIV immunoassay, more
than 50 HIV-negative human serum samples were evaluated.
The results demonstrated that r-HIV-MEP did not exhibit any
false positivity with normal human serum samples. These re-
sults unequivocally established the high degree of specificity of
r-HIV-MEP protein for the detection of anti-HIV antibodies.
Next, 57 serum samples from various well-characterized BBI
panels were used to evaluate our in-house r-HIV-MEP-based
anti-HIV immunoassay. Table 2 compares the ability of our
in-house assay to detect early seroconversion with those of
other commercial kits using a set of nine sera constituting the
HIV seroconversion panel (PRB 931). The earliest time point
at which seroconversion is detected in this panel is at 28 days,
using the in-house assay, represented by panel member 6. In
addition to our in-house assay, only one kit, namely, the Ab-
bott HIV-1/2 kit, out of the five commercial kits tested could
pick up this member. We assessed the sensitivity of the r-HIV-
MEP antigen to detect anti-HIV antibodies further by testing
it against BBI’s worldwide HIV performance panel (WWRB
302) consisting of 25 sera. Of these sera, 21 sera were HIV-1
positive, representing genotypes A, B, C, D, E, F, G, and O,
from diverse geographical locations such as the United States,
Spain, and several countries in Asia and Africa. Of the remain-
ing four sera in this panel, two were HIV-2 positive and two
were HIV negative (Table 3). Interestingly, the in-house im-
munoassay using r-HIV-MEP identified all 21 HIV-1 samples
and the 2 HIV-2 samples. Further, the two sera that were HIV
seronegative using five different commercial kits were also
seronegative in the in-house assay. To examine specificity in
the background of other infections, we evaluated the in-house
immunoassay using BBI’s viral coinfection panel consisting of
25 sera (PCA 201). Of these, 9 were HIV seronegative while
the rest (n 	 16) were HIV seropositive, based on commercial
assays. We tested 7 of the HIV-seronegative and all 16 of the
HIV-seropositive samples using the r-HIV-MEP-based immu-
noassay. Many of these samples were also seropositive for
hepatitis B virus (HBV), hepatitis C virus (HCV), and/or hu-
man T-cell leukemia virus (HTLV). The results are summa-
rized in Table 4. Significantly, regardless of the presence or
absence of antibodies to HBV, HTLV, or HCV, the results of
the in-house immunoassay for HIV antibodies closely matched
the results obtained with the commercial assays. The lone
exception was provided by panel member 20. This serum,
which scored as HIV positive with the commercial kits, was
assigned as HIV negative using the r-HIV-MEP-based assay. A
closer examination reveals that this discrepancy is attributable
to this sample being a borderline specimen. The S/Co ratios,
which must be1.0 to designate a sample as seropositive, were
1.1 and 1.0 for the two commercial kits and 0.9 for the in-house
assay.
Overall, the data show that the performance of our single
r-HIV-MEP-based immunoassay is in near total agreement
with the commercially available multiantigen-based anti-HIV
EIA kits, namely, Abbott HIV-1, Abbott HIV-1/2, Genetic
Systems HIV-1, Genetic Systems HIV-1/2, and Organon
Teknika HIV-1.
DISCUSSION
Our earlier work has established the utility of recombinant
MEPs in the detection of infection by different pathogens (1, 2,
6). The present study is based on the premise that the use of a
single diagnostic intermediate designed to have HIV-specific
immunodominant epitopes from all known genotypes and ex-
pressed to high levels in an E. coli expression system could
effectively address the issues of cost and specificity associated
with the currently available multiple-antigen-based anti-HIV
diagnostic assays. To develop this recombinant antigen, we
focused on the HIV-1 and HIV-2 antigens shown in Table 1.
The ability of these proteins to elicit humoral immune re-
sponse has been well documented, and their antigenic deter-
minants have been identified using a variety of different ap-
proaches (4, 13, 16). We selected immunodominant, linear,
and phylogenetically conserved epitopes from these antigens
for incorporation into the synthetic antigen r-HIV-MEP. In
order for a synthetic MEP to be capable of efficiently recog-
nizing HIV-specific antibodies, it is necessary that its constit-
TABLE 2. Evaluation of r-HIV-MEP-based indirect immunoassay using HIV seroconversion panel (PRB 931; Boston Biomedica Inc.)
Member ID Bleeddatea
Days since
first bleed
S/Co value
Abbottb Gen. Sys.b
OT HIVb MEPc
HIV-1 HIV-1/2 HIV-1 HIV-1/2
01 14 0 0.2 0.1 0.2 0.1 0.3 0.1 (
)
02 16 2 0.2 0.1 0.1 0.1 0.3 0.2 (
)
03 21 7 0.2 0.1 0.2 0.1 0.4 0.3 (
)
04 23 9 0.2 0.1 0.2 0.1 0.3 0.3 (
)
05 29 15 0.2 0.1 0.2 0.1 0.3 0.3 (
)
06 11 28 0.9 6 0.3 0.4 0.6 1.2 ()
07 16 33 3.9 18.7 0.8 1.1 2.3 5.6 ()
08 18 35 5.7 18.7 1.3 1.9 3.1 9.2 ()
09 25 42 10.5 18.7 2.9 4 4.6 10 ()
a Bleed dates for member IDs 01 to 05 were in August 1995; those for IDs 06 to 09 were in September 1995.
b Values indicate signal-to-cutoff ratios provided by the panel supplier (Gen. Sys., Genetic Systems; OT, Organon Teknika) using the indicated commercial kits. S/Co
values 1.0 are considered positive.
c Values indicate signal-to-cutoff ratios obtained using the in-house indirect immunoassay. The results using the in-house assay are indicated in parentheses. Samples
with S/Co values 1.0 are designated negative (
), and those with values 1.0 are designated positive ().
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uent epitopes exhibit significant reactivity to HIV-infected pa-
tient sera worldwide. Since we wanted to use E. coli-based
overexpression from the cost perspective, it was necessary to
work with linear epitopes, so that when incorporated into the
synthetic protein, they would presumably retain their immu-
noreactivity toward anti-HIV antibodies. Finally, the phyloge-
netically conserved epitopes would facilitate the recognition of
multiple HIV types and groups. The selected epitopes, which
ranged in length from 28 to 51 amino acid (aa) residues, were
fused in frame using flexible tetraglycyl linkers between adja-
cent epitopes. These linkers are preferred in designing flexible
chimeric proteins (20). Computer modeling analysis of the
MEP antigen which showed all the chosen epitopes to be
accessible suggested that they would collectively contribute to
the overall specificity and sensitivity of the molecule.
We overexpressed the recombinant antigen in E. coli and
purified it under denaturing conditions, as it was insoluble
despite its fusion to thioredoxin. We then evaluated the effi-
cacy of r-HIV-MEP as a diagnostic intermediate in an in-house
Eu3-9d-chelate-based indirect immunoassay. In this assay we
used the recombinant protein as the capture antigen and pan-
els of HIV-infected (commercially available) and normal hu-
man sera as test samples. We then used anti-human antibody
labeled with Eu3-9d-chelate as a tracer and monitored cap-
tured anti-HIV antibody through TRF. The results showed
that our synthetic diagnostic intermediate could indeed recog-
nize and bind to anti-HIV antibodies, elicited by both HIV-1
and HIV-2. However, it is to be noted that the design of
r-HIV-MEP precludes differentiation of HIV-1 from HIV-2.
As HIV exhibits a distinct geographical distribution, a world-
wide HIV performance panel (WWRB 302) was used to eval-
uate if r-HIV-MEP could recognize the HIV-infected sera
from different parts of the world. Panel members included
specimens characterized as HIV-1 group M (subtypes A to G),
HIV-1 group O, and HIV-2. Our results demonstrated that
r-HIV-MEP was able to recognize antibodies to a diverse set of
HIV infections from India and from other countries such as
Argentina, China, Ghana, Ivory Coast, Mozambique, Spain,
Thailand, Uganda, the United States, and Zimbabwe. The
HIV seroconversion panel (PRB 931) was utilized to evaluate
the sensitivity of the r-HIV-MEP in the immunoassay, and the
results were found to be in complete agreement with those of
the best-performing Abbott HIV-1/2 EIA kit in the early di-
agnosis of anti-HIV antibodies in human sera. Our immuno-
assay was able to pick up panel member 6 of the HIV sero-
conversion panel (PRB 931), which showed immunoreactivity
with the Abbott HIV-1/2 EIA kit only and not with other EIA
kits. The viral coinfection panel (PCA 201), on the other hand,
was used for the evaluation of specificity of the r-HIV-MEP in
the immunoassay. This single diagnostic intermediate per-
formed as well as the other commercial anti-HIV kits from
Abbott, Genetic Systems, and Organon Teknika except for
TABLE 3. Evaluation of r-HIV-MEP-based indirect immunoassay using worldwide HIV performance panel
(WWRB 302; Boston Biomedica Inc.)
Member ID Origin Gtypa
S/Co value
Abbottb Gen. Sys.b
OT HIV-1b MEPc
HIV-1 HIV-1/2 HIV-1 HIV-1/2
01 Spain O 1.1 1.8 0.8 5.6 1.3 10 ()
02 Ghana A 11.5 16.1 6.9 8.7 7.0 10 ()
03 Ghana G 11.5 16.1 7.1 8.8 7.2 10 ()
04 Ghana G 11.5 16.1 7.1 8.8 6.5 10 ()
05 Ghana A 11.5 16.1 7.1 8.7 7.0 1.8 ()
06 Ghana G 11.5 16.1 6.9 8.8 7.1 9.2 ()
08 Ivory Coast G 11.5 16.1 6.9 8.7 6.7 10 ()
09 Ivory Coast A 11.5 16.1 6.9 8.6 6.5 10 ()
10 Ivory Coast Negd 0.4 0.2 0.1 0.4 0.4 0.5 (
)
11 Mozambique HIV-2 1.2 14.6 0.6 9.7 3.0 1.8 ()
12 Mozambique C 11.5 16.1 7.1 8.9 6.9 10 ()
14 Uganda D 11.5 16.1 4.5 8.5 6.2 6.4 ()
15 Uganda D 11.5 16.1 6.3 8.1 7.2 3.5 ()
16 Uganda D 11.5 16.1 7.0 8.8 6.9 8.8 ()
17 Uganda D 11.5 16.1 6.8 9.8 7.0 2.7 ()
19 Zimbabwe C 11.5 16.1 6.0 9.9 7.0 10 ()
21 China B 11.5 16.1 6.7 8.8 7.0 10 ()
22 Thailand E 11.5 16.1 7.3 9.8 7.0 10 ()
24 Thailand E 11.5 16.1 7.4 9.8 6.9 10 ()
25 India HIV-2 0.4 15.4 3.8 10 2.1 10 ()
26 USA D 11.5 16.1 7.4 9.8 7.1 10 ()
27 USA B/D 11.5 16.1 7.0 9.8 7.2 10 ()
28 Argentina F 11.5 16.1 7.0 8.9 6.8 10 ()
29 Argentina B 11.5 16.1 6.9 8.5 6.6 10 ()
30 Argentina Neg 0.3 0.2 0.2 0.2 0.4 0.3 (
)
a Gtyp, genotype.
b Values indicate signal-to-cutoff (S/Co) ratios, provided by the panel supplier (Gen. Sys., Genetic Systems; OT, Organon Teknika) using the indicated commercial
kits. S/Co values 1.0 are considered positive.
c Values indicate signal-to-cutoff ratios obtained using the in-house indirect immunoassay. The results using the in-house assay are indicated in parentheses. Samples
with S/Co values 1.0 are designated negative (
), and those with values 1.0 are designated positive ().
d Neg, negative.
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panel member 20 of the viral coinfection panel, which hap-
pened to be a borderline sample. The information regarding
the subtype of this member is unavailable. Overall, the data
attest to the utility of our designer antigen in detecting HIV
infection, from diverse geographical locations, with high spec-
ificity and sensitivity. It is also useful in monitoring serocon-
version. However, these are preliminary data and need to be
corroborated with a larger number of serum samples. The use
of fluorescent Eu3-9d-chelate enables simplified, rapid, and
universal test protocols to be constructed for a wide range of
analytical applications because of the ease of antibody labeling
with Eu3-9d-chelate and easy measurement of fluorescence
directly from the dry wells without adding any substrate or
stopping the reaction. Though the current assay takes a few
hours, it has the potential to be adapted to a rapid test format.
In conclusion, the high density of HIV-specific, phylogeneti-
cally conserved, and immunodominant epitopes selected for
designing the r-HIV-MEP contributed to a high degree of
sensitivity and specificity. Further, our strategy of using a single
recombinant MEP completely obviates multiple peptide syn-
thesis and multiple protein expressions, and our Eu3-9d-che-
late-labeled antibody as a tracer further simplifies the immu-
noassay. These factors, together with the high level of
expression of r-HIV-MEP in E. coli and its single-step affinity
purification design, make this approach highly cost-effective
for anti-HIV screening in blood banks in most developing
countries. The yield of purified r-HIV-MEP from 1 liter of
induced culture is sufficient for 40,000 assays.
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